University Home | Hospital | Pulse Employment | Contact Us | Search | News 
Thomas Jefferson University Search Jefferson
Jefferson Medical College Jefferson College of Graduate Studies Jefferson College of Health Professions
Menu

Thomas Jefferson University - Jianqing Lin
Jianqing Lin

Medical Oncology
Thomas Jefferson University
Jefferson Medical Coloege
Department of Medical Oncology
Assistant Professor
Appointed: 2009
Image Placeholder
Mailing Address
834 Chestnut Street, Suite 314
Philadelphia, Pennsylvania 19107
United States
Contact Information
Phone: 215-955-8874
Fax: 215-503-7515
jianqing.lin@jefferson.edu
Qualifications
M.D., Zhejiang Medical University, 1986

M.S., Shanghai Medical University, 1992

M.A., Marshall University School of Medicine, 1997
Expertise and Research Interests
Drug development and clinical trials. Translational and clinical research on biomarkers to guide therapy.
Languages
Chinese and English
Publications
  • Selected Peer-Reviewed Publications

  • Lin JQ, Kong XS. And Cheng L.: Retinoic acid induces differentiation of human T lymphocytic leukemia CCRF-CEM cells. Chung- Hua-Chung-Liu-Tsa-Chih 15,339-342(1993) (Chinese Journal of Oncology)

  • Lin J, Kong X and Cheng L, "A study of effects and mechanism of retinoic acid on inducing differentiation of mouse lymphoma SACIIB2 clone cells." Acta Academiae Medicinae Shanghai 21:293- 296(1994)

  • Lin JQ, Xu ZS., Zhang HY., Yang ZH., Xu YH.: An EGFR antisense oligodeoxynucleotides and its phosphorothioate analogues inhibit the growth of human hepatocarcinoma BEL-7404 cells. Shih-Yen-Sheng-Wu-Hsueh-Pao 28:241-6, 1995 (Acta Biologica Experimenta)

  • Lin J., Adam R., and Freeman M.: The phosphatidylinositol 3-kinase pathway is a dominant growth factor-activated cell survival pathway in LNCaP human prostate carcinoma cells. Cancer Res 59:2891-97, 1999.

  • Nguyen HT, Bride SH, Badawy AB, Adam RM, Lin J, Orsola A, Guthrie PD, Freeman MR, Peters CA.: Heparin-binding EGF-like growth factor is up- regulated in the obstructed kidney in a cell- and region-specific manner and acts to inhibit apoptosis. Am J Pathol 156(3): 889-98, 2000

  • Lin J., Hutchinson L., Gaston SM., Raab G., and Freeman MR.: BAG-1 is a novel cytoplasmic binding partner of the membrane form of heparin-binding EGF-like growth factor, a unique role for proHB-EGF in cell survival regulation. J Biol Chem 276:30127- 30132, 2001

  • Duque JL, Adam RM, Mullen JS, Lin J, Richie JP, and Freeman MR.: Heparin-binding epidermal growth factor-like growth factor is an autocrine mediator of human prostate stromal cell growth in vitro. J Urol 165(1): 284-8, 2001

  • Zhuang L, Lin J, Lu ML, Solomon KR, Freeman MR.: Cholesterol-rich lipid rafts mediate Akt-regulated survival in prostate cancer cells. Cancer Res 62(8): 2227-31, 2002

  • Adam RA, Kim J., Lin J., Orsola A., Zhuang L., Rice DC, and Freeman MR.: Heparin-binding EGF-like growth factor stimulates androgen-independent prostate tumor growth and antagonizes androgen receptor function. Endocrinology 143(12):4599-608,2002

  • Lin J. and Freeman MR.: Transactivation of ErbB1 and ErbB2 receptors by angiotensin II in normal human prostate stromal cells. Prostate 54(1):1-7, 2003

  • Adam RM, Danciu T, McLellan DL, Borer JG, Lin J, Zurakowski D, Weinstein MH, Rajjayabun PH, Mellon JK, Freeman MR. A nuclear form of the heparin-binding epidermalgrowth factor-like growth factor precursor is a feature of aggressive transitional cell carcinoma. Cancer Res. 63(2):484-90 2003

  • Kim J, Lin J., Adam RM, Lamb C, Shively SB, Freeman MR. An oxidative stress mechanism medicates chelerythrine-Induced Heparin-Binding EGF-like growth factor ectodomain shedding. J Cell Biochem. 94(1):39-49,2005

  • Lin J, Gilbert J, Rudek MA, Zweibel JA, Zhao M, Jiemjit A, Baker SD, Ambinder RF, Herman JG, Gore S, Donehower RC, Carducci MA : A Phase I/II Dose Finding Study of 5-Azacytidine in Combination with Sodium phenybutyrate in Patients with Refractory Solid Tumors. Clinical Cancer Research 15(19):6241-9, 2009

  • Lin J, Michael A Carducci: HIF-1± inhibition as a novel mechanism of cardiac glycosides in cancer therapeutics, Expert Opinion on Investigational Drugs 18 (2):241-243, 2009

  • Lin J, Denmeade S, Carducci MA: HIF-1± and calcium signaling as targets for treatment of prostate cancer by cardiac glycosides (Current Cancer Drug Target, 2009, in press)

  • Lin J, Sinibaldi VJ, Carducci MA, DeWeese T, Denmeade S, and Song D, Eisenberger MA,.: Phase I Trial with a Combination of Docetaxel (Tax) and 153 Sm-EDTMP (Sm) in Patients with Metastatic Castrate Resistant Prostate Cancer (mCRPC) (Urologic Oncology, 2009, in press)

  • Lin J, Donehower R: Make quality cancer survivorship care possible in the era of workforce shortage (Journal of Oncology Practice, 2010, in press)

Individual Expertise profile of Jianqing Lin, Copyright © Jianqing Lin.
Last Updated by Admin : Thursday, December 24, 2009 10:06:33 AM



Maintained by Jefferson Information Technologies
Copyright © Thomas Jefferson University. All Rights Reserved.

 Printable Version

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement.
Thomas Jefferson University